Diabetic Foot Care: Evidence‑Based Recommendations
Screening and Risk Stratification
- All adults with diabetes should receive a comprehensive foot screening at least once per year, with screening frequency intensified according to IWGDF risk level (annual for Risk 0, every 6–12 months for Risk 1, every 3–6 months for Risk 2, and every 1–3 months for Risk 3)【@1】.
- The International Working Group on Diabetic Foot (IWGDF) classification system is the recommended framework for risk assessment in diabetic foot care【@1】.
Comprehensive Screening Components
- Annual screening must evaluate peripheral neuropathy and peripheral artery disease (PAD) using validated clinical tests【@4】.
- Neuropathy assessment should include: 10 g Semmes‑Weinstein monofilament at three plantar sites, 128‑Hz tuning fork vibration perception, pin‑prick discrimination, light‑touch testing with cotton wool or fingertip, and Achilles tendon reflexes【@5】.
- Vascular assessment should comprise history of claudication or rest pain, palpation of pedal pulses, capillary refill time, rubor on dependency, pallor on elevation, venous filling time, and Doppler ultrasound with pulse‑volume recordings when PAD is suspected【@3】.
- Document additional risk factors such as prior ulcer or amputation, foot deformities (e.g., claw or hammer toes), limited joint mobility, pre‑ulcerative signs (callus, blisters, hemorrhage), fungal infection, and inadequate footwear【@4】.
Patient Education and Daily Foot Care (Risk 1‑3)
- Structured education must be provided to all at‑risk patients on daily foot inspection, hygiene, nail care, and avoidance behaviours【@1】.
- Patients should inspect their feet and the interior of shoes every day, using a mirror if needed, and contact a healthcare provider immediately for any temperature increase, blisters, cuts, scratches, ulcers, or color changes【@1】.
- Daily hygiene includes washing feet with water below 37 °C, drying carefully (especially between toes), and applying emollients to dry skin but not between toes【@1】.
- Toenails should be cut straight across; nails must not be cut too short or rounded at the corners【@1】.
- Patients must never walk barefoot, wear only socks, use thin‑soled slippers, apply chemical agents or plasters to remove calluses, use heating pads or hot water bottles on the feet, or wear tight/knee‑high socks with constricting bands【@1】.
Footwear Recommendations
- Risk 1‑3 without deformity or ulcer history: Use properly fitting shoes that accommodate foot shape, inspect the interior of shoes before wearing, and avoid shoes with rough edges or uneven seams【@1】.
- Risk 2‑3 with foot deformity or pre‑ulcerative lesions: Prescribe extra‑depth shoes, custom‑made footwear, custom insoles, or toe orthoses as needed【@1】.
- Risk 3 with healed plantar ulcer: Provide therapeutic footwear that achieves at least a 30 % reduction in plantar pressure compared with standard therapeutic shoes; encourage consistent indoor and outdoor use【@4】.
Evidence level: Strong recommendation, moderate quality evidence【@4】.
Professional Management of Pre‑Ulcerative Lesions
- Callus removal should be performed by a qualified professional; self‑treatment is discouraged【@4】.
- Blisters should be protected and drained when necessary; ingrown or thickened toenails, hemorrhage, and fungal infections should be treated promptly by a clinician【@4】.
Advanced Monitoring for High‑Risk Patients (Risk 2‑3)
- Daily home foot‑temperature monitoring is recommended; patients should measure skin temperature on corresponding regions of both feet【@8】.
- If the temperature difference exceeds 2.2 °C (4.0 °F) on two consecutive days, patients should reduce ambulatory activity and contact their healthcare provider immediately【@1】.
Evidence level: Moderate‑quality evidence supporting ulcer prevention【@1】.
Integrated Care and Follow‑Up (Risk 2‑3)
- An integrated approach combining professional lesion treatment, appropriate footwear, and structured education is advised【@4】.
- Re‑evaluation intervals: every 1–3 months for Risk 3 patients and every 3–6 months for Risk 2 patients【@4】.
Recommendation strength: Strong, despite low‑quality evidence【@4】.
Multidisciplinary Team Approach (High‑Risk)
- Refer patients on dialysis, with Charcot foot, prior ulcer/amputation, or PAD to podiatry services; refer smokers with prior complications, loss of protective sensation, structural abnormalities, or PAD to foot‑care specialists for lifelong surveillance【@3】.
- Provide smoking‑cessation counseling to all smokers【@3】.
Surgical Options for Refractory Cases
- Digital flexor tenotomy is indicated for non‑rigid hammertoes with pre‑ulcerative lesions or distal toe ulcers【@8】.
- Achilles tendon lengthening, metatarsal head resection, or osteotomy may be considered for recurrent plantar forefoot ulcers【@8】.
- Nerve decompression procedures are not recommended due to lack of supporting evidence【@11】.
Exercise Recommendations (Risk 1‑2)
- Implement an 8–12‑week supervised foot‑ankle exercise program, followed by continued home exercises【@10】.
- Increasing daily walking by approximately 1,000 steps is considered safe when patients wear appropriate footwear and monitor for lesions【@10】.
Common Pitfalls to Avoid
- Failing to stratify risk and adjust screening frequency leads to missed early disease—annual screening alone is insufficient for high‑risk patients【@1】.
- Inadequate patient education about never walking barefoot indoors is a frequent error【@1】.
- Standard therapeutic shoes are ineffective for healed plantar ulcers; only footwear with documented ≥30 % pressure reduction provides benefit【@4】.
- Allowing patients to self‑treat calluses with over‑the‑counter products can cause chemical burns and ulceration【@4】.
Diagnosis and Management of Bullous Lesions in Diabetic Patients (Bullosis Diabeticorum)
Diagnostic Evaluation
- Perform a skin biopsy with direct immunofluorescence (DIF) to exclude bullous pemphigoid; bullosis diabeticorum typically shows negative DIF, whereas bullous pemphigoid displays linear IgG and/or C3 deposits along the dermo‑epidermal junction. 1
- Review recent use (1–6 months) of dipeptidyl‑peptidase‑4 (DPP‑4) inhibitors, as these agents can precipitate bullous pemphigoid in diabetic patients. 1
- If DIF is positive, follow with indirect immunofluorescence on salt‑split skin and ELISA for anti‑BP180/BP230 antibodies to confirm bullous pemphigoid. 1
Acute Wound Care
- Preserve intact bullae initially to maintain the natural barrier and avoid premature rupture. 2
- Drain large or tense bullae using sterile technique when necessary to prevent secondary infection. 2
- Debride ruptured bullae by removing non‑viable tissue; the frequency of sharp debridement should be guided by clinical need. 3
- Apply simple protective dressings; topical antiseptics, antimicrobial agents, honey, collagen, or alginate dressings do not enhance healing in diabetic wounds. [3][4]5
Offloading and Foot Protection
- Implement strict offloading for lower‑extremity lesions: patients should never walk barefoot and should wear only socks or thin‑soled slippers indoors and outdoors. [2][6]7
- Provide therapeutic footwear that achieves ≥30 % plantar pressure reduction for patients with healed plantar lesions and peripheral neuropathy (IWGDF risk level 3). [6][8]
- Instruct patients to perform daily foot inspection (using a mirror if needed) and to report any new blisters, temperature changes, cuts, or discoloration immediately. [6][7]
- Recommend foot hygiene: wash feet with water below 37 °C, dry carefully between toes, apply emollient to dry skin (excluding interdigital spaces), and trim toenails straight across. [6][7]8
Follow‑Up and Surveillance
- Classify patients using the International Working Group on the Diabetic Foot (IWGDF) risk system; bullosis diabeticorum patients have at least risk level 1 due to peripheral neuropathy. 7
- Schedule follow‑up based on risk: every 6–12 months for risk 1, every 3–6 months for risk 2, and every 1–3 months for risk 3. [7][8]
- Deliver integrated foot care (professional lesion treatment, appropriate footwear, structured education) at each visit for risk 2–3 patients. [6][9]10
- Advise home foot‑temperature monitoring: if a temperature difference >2.2 °C between corresponding sites persists for two consecutive days, patients should reduce activity and contact their provider promptly. [6][9]8